Churchill Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9M | Buy |
371,083
+44,218
| +14% | +$1.03M | 0.1% | 83 |
|
|
2025
Q1 | $8.28M | Buy |
+326,865
| New | +$8.55M | 0.11% | 83 |
|
|
2024
Q4 | – | Sell |
-525,499
| Closed | -$15.2M | – | 167 |
|
|
2024
Q3 | $15.2M | Buy |
+525,499
| New | +$15.3M | 0.17% | 48 |
|
|
2023
Q2 | – | Sell |
-33,472
| Closed | -$1.37M | – | 156 |
|
|
2023
Q1 | $1.37M | Sell |
33,472
-322,220
| -91% | -$13.9M | 0.03% | 124 |
|
|
2022
Q4 | $18.2M | Sell |
355,692
-14,710
| -4% | -$705K | 0.44% | 24 |
|
|
2022
Q3 | $16.2M | Buy |
370,402
+48,580
| +15% | +$2.36M | 0.43% | 24 |
|
|
2022
Q2 | $16.9M | Sell |
321,822
-766
| -0.2% | -$39K | 0.42% | 24 |
|
|
2022
Q1 | $16.7M | Buy |
322,588
+21,444
| +7% | +$1.11M | 0.29% | 30 |
|
|
2021
Q4 | $17.8M | Buy |
301,144
+10,356
| +4% | +$513K | 0.25% | 41 |
|
|
2021
Q3 | $12.5M | Buy |
+290,788
| New | +$12.9M | 0.19% | 57 |
|
|
2021
Q1 | – | Sell |
-416,026
| Closed | -$15.3M | – | 153 |
|
|
2020
Q4 | $15.3M | Sell |
416,026
-60,245
| -13% | -$2.21M | 0.26% | 47 |
|
|
2020
Q3 | $16.6M | Sell |
476,271
-54,774
| -10% | -$1.92M | 0.41% | 28 |
|
|
2020
Q2 | $16.5M | Sell |
531,045
-39,671
| -7% | -$1.35M | 0.51% | 25 |
|
|
2020
Q1 | $17.7M | Buy |
+570,716
| New | +$19.4M | 0.89% | 12 |
|
|
2019
Q4 | – | Sell |
-22,457
| Closed | -$766K | – | 131 |
|
|
2019
Q3 | $766K | Sell |
22,457
-146,144
| -87% | -$5.31M | 0.02% | 103 |
|
|
2019
Q2 | $6.93M | Buy |
168,601
+629
| +0.4% | +$25K | 0.19% | 69 |
|
|
2019
Q1 | $6.77M | Buy |
167,972
+3,644
| +2% | +$146K | 0.18% | 66 |
|
|
2018
Q4 | $6.8M | Sell |
164,328
-2,753
| -2% | -$114K | 0.3% | 49 |
|
|
2018
Q3 | $6.99M | Sell |
167,081
-3,207
| -2% | -$123K | 0.15% | 67 |
|
|
2018
Q2 | $5.86M | Sell |
170,288
-12,023
| -7% | -$411K | 0.16% | 68 |
|
|
2018
Q1 | $6.14M | Sell |
182,311
-7,867
| -4% | -$270K | 0.18% | 63 |
|
|
2017
Q4 | $6.54M | Sell |
190,178
-7,373
| -4% | -$251K | 0.14% | 59 |
|
|
2017
Q3 | $6.69M | Sell |
197,551
-12,905
| -6% | -$415K | 0.16% | 53 |
|
|
2017
Q2 | $6.71M | Buy |
210,456
+125,234
| +147% | +$3.95M | 0.18% | 52 |
|
|
2017
Q1 | $2.77M | Sell |
85,222
-478,359
| -85% | -$15.1M | 0.08% | 94 |
|
|
2016
Q4 | $17.4M | Buy |
563,581
+27,743
| +5% | +$847K | 0.58% | 35 |
|
|
2016
Q3 | $17.2M | Buy |
535,838
+51,809
| +11% | +$1.73M | 0.7% | 31 |
|
|
2016
Q2 | $16.2M | Buy |
484,029
+49,902
| +11% | +$1.59M | 1.06% | 25 |
|
|
2016
Q1 | $12.2M | Buy |
434,127
+41,195
| +10% | +$1.18M | 0.86% | 28 |
|
|
2015
Q4 | $12M | Buy |
392,932
+27,680
| +8% | +$871K | 0.57% | 29 |
|
|
2015
Q3 | $10.9M | Buy |
365,252
+801
| +0.2% | +$25.7K | 0.87% | 18 |
|
|
2015
Q2 | $11.6M | Buy |
364,451
+15,687
| +4% | +$511K | 0.41% | 34 |
|
|
2015
Q1 | $11.5M | Buy |
348,764
+58,111
| +20% | +$1.85M | 0.39% | 36 |
|
|
2014
Q4 | $8.59M | Buy |
290,653
+48,434
| +20% | +$1.39M | 0.34% | 33 |
|
|
2014
Q3 | $6.79M | Buy |
242,219
+35,435
| +17% | +$995K | 0.28% | 42 |
|
|
2014
Q2 | $5.82M | Buy |
206,784
+24,913
| +14% | +$710K | 0.26% | 49 |
|
|
2014
Q1 | $5.54M | Buy |
181,871
+16,312
| +10% | +$486K | 0.22% | 40 |
|
|
2013
Q4 | $4.81M | Buy |
165,559
+14,247
| +9% | +$415K | 0.18% | 41 |
|
|
2013
Q3 | $4.12M | Buy |
151,312
+14,551
| +11% | +$396K | 0.21% | 30 |
|
|
2013
Q2 | $3.63M | Buy |
+136,761
| New | +$3.78M | 0.17% | 41 |
|
Other funds holding PFE
Churchill Management's PFE Position: Q2 2025 in Review
Churchill Management increased its Pfizer (PFE) stake by 14% in Q2 2025, buying an estimated $1.03M and bringing the position to 371,083 shares worth $9M. The position accounts for 0.1% of the portfolio, ranked #83.
Churchill Management first reported a position in PFE in Q2 2013 and has held it in 40 quarters since. The position peaked at $18.2M in Q4 2022. 2,809 funds tracked by Wall St. Rank hold PFE as of Q2 2025.
- Churchill Management held 371,083 shares of Pfizer worth $9M as of Q2 2025.
- Churchill Management bought 44,218 Pfizer shares in Q2 2025, an estimated $1.03M.
- Pfizer made up 0.1% of Churchill Management's portfolio in Q2 2025, its #83 holding.
- Churchill Management first reported a position in Pfizer in Q2 2013 and has held it in 40 quarters since.
- Churchill Management's Pfizer position peaked at $18.2M in Q4 2022.
- 2,809 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.
Based on Churchill Management's 13F filing for Q2 2025, filed 18 Jul 2025.